News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, has announced that it has completed the rolling...
Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that it will join The Michael...
VAXIMM Appoints Thomas D. Szucs, MD, as Chairman of the Board
VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Thomas D. Szucs, MD, as Chairman of the Supervisory Board. He succeeds Thomas Hecht, MD, whose mandate ended in June 2020. Press...
Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has, based on the authorisation granted by the annual general meeting on 6 May 2020, resolved on a directed new share issue to selected Swedish and international institutional investors. In...
Orphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced...
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces topline results from a 6-month phase 2 dose-finding study in Gaucher disease with...